Company Description
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use.
In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities.
Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
| Country | Spain |
| Founded | 1940 |
| IPO Date | May 17, 2006 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 23,737 |
| CEO | Jose Ignacio Abia Buenache |
Contact Details
Address: Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158 Barcelona, 08174 Spain | |
| Phone | 34 935 71 22 00 |
| Website | grifols.com |
Stock Details
| Ticker Symbol | GRFS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001438569 |
| CUSIP Number | 398438408 |
| ISIN Number | US3984384087 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jose Ignacio Abia Buenache | Chief Executive Officer and Director |
| Rahul Srinivasan | Chief Financial Officer |
| Lluis Pons Gomez | Senior Vice President of Strategy and Chief Operating Officer Office |
| Daniel Segarra | Head of Investor Relations and Sustainability and Vice President |
| David Ian Bell | Chief Corporate Affairs and Legal Officer |
| Enrique de la Torre | Chief Compliance Officer |
| Montse Ribas | Chief Communications and Reputation Officer |
| Camille Alpi | Chief Human Resources and Talent Officer |
| Vicente Blanquer Torre | Chief Quality Officer |
| Sergio Roura Adell | President of Commercial Tech Support |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2026 | 6-K | Report of foreign issuer |
| Feb 26, 2026 | 6-K | Report of foreign issuer |
| Feb 26, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Jan 8, 2026 | 6-K | Report of foreign issuer |
| Dec 16, 2025 | 6-K | Report of foreign issuer |
| Nov 12, 2025 | SCHEDULE 13G/A | Filing |
| Nov 4, 2025 | 6-K | Report of foreign issuer |
| Sep 29, 2025 | 6-K | Report of foreign issuer |